Abstract:Conjugated bile acids (BA), as taurocholic acid (TCA) levels, are significantly elevated in several liver pathologies. The liver is the largest lymph producing organ and has a high density of lymphatic vessels but role of hepatic lymphatics is poorly understood. BAs accumulate in metastatic lymph nodes (LN), and the lymphatics are exposed to high levels of bile in liver disease. However, whether BAs play any role in enhancing pathological lymphangiogenesis that exacerbates liver inflammation remains completely unknown. BAs activate oxidative stress pathways in liver cells and promote injury. However, these mechanisms have not been studied in the context of lymphangiogenesis. We hypothesized that the BAs activate oxidative stress response pathways such as reactive oxygen species (ROS) and p90 ribosomal S6 kinase (p90RSK) pathways and promote lymphangiogenesis. BA levels were evaluated in serum and lymph nodes (LN) of wild type (WT, FVB/NJ) and Mdr2−/− mice (mouse model of primary sclerosing cholangitis, PSC). Lymphangiogenesis was assessed in the liver and LN from these animals. Human lymphatic endothelial cells (HLECs) were treated with TCDCA (100 µM), and TCA (100 µM) for 24hrs in the presence or absence of the specific BA receptor, Takeda G‐protein receptor 5 (TGR5) antagonist (SBI‐115), and changes in lymphangiogenic genes was assessed by qPCR. Effects on LEC proliferation, invasion, migration, and tube formation were also determined. Changes in LEC cellular bioenergetics was determined by Seahorse assay. BA levels were elevated in the LN and serum of Mdr2−/− mice compared to WT. Immunohistochemical staining of liver tissue sections with cholangiocyte marker (CK19) and lymphatic marker (LYVE1) showed increased lymphangiogenesis in the MDR2−/− mice compared to WT. BAs enhanced the expression of BA receptors, farnesoid X receptor (FXR), and TGR5 on HLECs and also increased HLEC tube formation, migration, and growth of lymphatic capillaries in a 3‐D collagen matrix that was inhibited by SBI‐115, ROS inhibitor (NAC), and p90RSK inhibitor (BI‐D1870). A significant increase in maximal glycolytic capacity and ATP production was observed in the HLECs in response to BA treatment. BAs enhanced mitochondrial ROS and phosphorylated the redox‐sensitive kinase p90RSK (S380), an essential regulator of endothelial cell dysfunction in a ROS‐dependent manner. BAs also induced Prospero homeobox 1 (Prox1) SUMOylation via p90RSK activation and enhanced VEGFR3 expression, which was inhibited by BI‐D1870 and NAC. Overall, our data suggest that BA‐induced p90RSK activation plays a crucial role in the induction Prox1‐VEGFR3 axis as the precursor of lymphangiogenesis and activates a feedback loop between cellular ROS and oxidative stress activation pathways that could further promote liver injury and inflammation.

Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis

Ratio Of Conjugated Chenodeoxycholic To Muricholic Acids Is Associated With Severity Of Nonalcoholic Steatohepatitis

Dysregulated Hepatic Bile Acids Collaboratively Promote Liver Carcinogenesis

6824 Bile Acid Elevation in Nonalcoholic Steatohepatitis Correlates With Fibrogenesis and Mitochondrial Dysfunction In Vitro

Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation

Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma

Antifibrotic Effects of a Barbituric Acid Derivative on Liver Fibrosis by Blocking the NF-κB Signaling Pathway in Hepatic Stellate Cells

Bruceine A attenuates fibrogenesis and inflammation through NR2F2-regulated HMGB1 inflammatory signaling cascades in hepatic fibrosis

Dysregulated bile acid synthesis, metabolism and excretion in a high fat-cholesterol diet-induced fibrotic steatohepatitis in rats

Conjugated Bile Acids activate Reactive Oxygen Species‐p90RSK‐Vascular Endothelial Growth Factor Receptor 3 signaling axis to promote lymphangiogenesis

Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease

Combination of Pirfenidone and Andrographolide Ameliorates Hepatic Stellate Cell Activation and Liver Fibrosis by Mediating TGF- β/Smad Signaling Pathway

Upregulation of Cadherin-11 Contributes to Cholestatic Liver Fibrosis

Glycocholic Acid Aggravates Liver Fibrosis by Promoting the Up-Regulation of Connective Tissue Growth Factor in Hepatocytes.

Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis

Multitranscriptome analyses reveal prioritized genes specifically associated with liver fibrosis progression independent of etiology

Loss of SLC27A5 Activates Hepatic Stellate Cells and Promotes Liver Fibrosis via Unconjugated Cholic Acid

Bile acids attenuate hepatic inflammation during ischemia/reperfusion injury

Effects of Therapeutically Approved Individual Bile Acids on The Development of Metabolic Dysfunction-Associated Steatohepatitis a Low Bile Acid Mouse Model

Betulinic Acid Improves Nonalcoholic Fatty Liver Disease Through YY1/FAS Signaling Pathway

Bile acids associate with specific gut microbiota, low‐level alcohol consumption and liver fibrosis in patients with non‐alcoholic fatty liver disease